Home
About Us
Group Introduction
Founder Introduction
Global Cooperation
Nanolattix Biotechnology
Company Profile
Development History
Research Layout
Nanolattix Health
Extraction Platform
Cosmetics
Machine
Food Brand
Disinfection
Oem/Odm
News
Company News
Industry News
Contact Us
简体中文
English
Release time:
2025-01-10
Nanolattix's Innovative Drug T320 Receives Clinical Trial Approval from Australia's TGA
Tag:
Previous Page
2024.12
2024.9
Next Page
Previous Page:
Next page:
recommend News
Nanolattix Chairperson Dr. Zhican Qu Attends BIO 2025, Showcasing China's Biopharma Innovation
2025-07-09
Clinical Trial Recruitment for T320, a Novel TF-Targeting Anti-Cancer Drug
Nanolattix’s T320-ADC Multi-Center Clinical Trials Initiated, Accelerating Development of Advanced Solid Tumor Therapies
Media Focus | Tonacea: Under the Dual-Mode Narrative, Nanolattix Launches a Synergistic Offensive
2026-04-27
Nanolattix Chairman Qu Zhican Invited to Attend 3rd Radiopharmaceutical Development Summit, Collaborates to Shape RDC Innovation Landscape
2026-03-27
Share
